China Delays U.S. Plans To Open Three FDA Foreign Offices
This article was originally published in PharmAsia News
U.S. plans to open a drug-inspection office in China have hit a snag over diplomatic visas. U.S. FDA plans to establish offices in Beijing, Shanghai and Guangzhou, staffed by 13 employees. The Chinese government has endorsed the idea, but the Ministry of Foreign Affairs has not given its formal approval. The agency wants to set up the offices to give it greater ability to ensure the safety of drug products exported to the United States. Once the China offices are opened, FDA has similar plans for India. (Click here for more - a subscription may be required
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.